ArticleOncogene2009
Sprouty4 negatively regulates protein kinase C activation by inhibiting phosphatidylinositol 4,5-biphosphate hydrolysis.
Article in Oncogene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53.Nature communications · 2024Article
- Role of SPRY4 in health and disease.Frontiers in oncology · 2024Review
- Regulation of positive and negative selection and TCR signaling during thymic T cell development by capicua.eLife · 2021Article
- SOCS, SPRED, and NR4a: Negative regulators of cytokine signaling and transcription in immune tolerance.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2021Article
- Article
- Endothelial CaInternational journal of molecular sciences · 2019Review
- Sprouty2-a Novel Therapeutic Target in the Nervous System?Molecular neurobiology · 2019Review
- The matrix domain of the Gag protein from avian sarcoma virus contains a PI(4,5)PThe Journal of biological chemistry · 2018Article
- Analysis of the ways and methods of signaling pathways in regulating cell cycle of NIH3T3 at transcriptional level.BMC cell biology · 2015Article
- Autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation.Cell death & disease · 2015Article
- Article
- The developing story of Sprouty and cancer.Cancer metastasis reviews · 2014Review
- Sprouty4 is an endogenous negative modulator of TrkA signaling and neuronal differentiation induced by NGF.PloS one · 2012Article
- Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins.The Journal of biological chemistry · 2011Article
- Characterisation of a new regulator of BDNF signalling, Sprouty3, involved in axonal morphogenesis in vivo.Development (Cambridge, England) · 2010Article
- FGF signalling: diverse roles during early vertebrate embryogenesis.Development (Cambridge, England) · 2010Review
- Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C.Molecular biology of the cell · 2010Article
- Kidney development in the absence of Gdnf and Spry1 requires Fgf10.PLoS genetics · 2010Article
- Intermolecular interactions of Sprouty proteins and their implications in development and disease.Molecular pharmacology · 2009Review
- Sprouty4 deficiency potentiates Ras-independent angiogenic signals and tumor growth.Cancer science · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sproutys have been shown to negatively regulate growth factor-induced extracellular signal-regulated kinase (ERK) activation, and suggested to be an anti-oncogene. However, molecular mechanism of the suppression has not yet been clarified completely. Sprouty4 inhibits vascular endothelial growth factor (VEGF)-A-induced ERK activation, but not VEGF-C-induced ERK activation. It has been shown that VEGF-A-mediated ERK activation is strongly dependent on protein kinase C (PKC), whereas that by VEGF-C is dependent on Ras. This suggests that Sprouty4 inhibits the PKC pathway more specifically than the Ras pathway. In this study, we confirmed that Sprouty4 suppressed various signals downstream of PKC, such as phosphorylation of MARCKS and protein kinase D (PKD), as well as PKC-dependent nuclear factor (NF)-kappaB activation. Furthermore, Sprouty4 suppressed upstream signals of PKC, such as Ca(2+) mobilization, phosphatidylinositol 4,5-biphosphate (PIP(2)) breakdown and inositol 1,4,5-triphosphate (IP(3)) production in response to VEGF-A. Those effects were dependent on the C-terminal cysteine-rich region, but not on the N-terminal region of Sprouty4, which is critical for the suppression of fibroblast growth factor (FGF)-mediated ERK activation. Sprouty4 overexpression or deletion of the Sprouty4 gene did not affect phospholipase C (PLC) gamma-1 activation, which is an enzyme that catalyzes PIP(2) hydrolysis. Moreover, Sprouty4 inhibited not only VEGF-A-mediated PIP(2) hydrolysis but also inhibited the lysophosphatidic acid (LPA)-induced PIP(2) breakdown that is catalyzed by PLC beta/epsilon activated by G-protein coupled receptor (GPCR). Taken together, Sprouty4 has broader suppression activity for various stimuli than previously thought; it may function as an inhibitor for various types of PLC-dependent signaling as well as for ERK activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.